Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Engineered Dendritic Cell Vaccines for Multiple Myeloma — Stella

Home/Multiple Myeloma or Plasmacytoma/Engineered Dendritic Cell Vaccines for Multiple Myeloma

View on ClinicalTrials.gov

Recruiting

Back to Multiple Myeloma or Plasmacytoma trials

Engineered Dendritic Cell Vaccines for Multiple Myeloma

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(2 sites)

China

Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong

Russia

The Regional Hematology Center in Clinical Hospital No. 2 of the Ministry of Health, Vladivostok

Key details

Phase

Early testing

Sponsor

Shenzhen Geno-Immune Medical Institute

Collaborators

The No.2 Clinical Hospital of the Ministry of Health

Enrollment target

~10 participants

Started

May 2024

Primary completion

July 2027

Age range

18 Years – 80 Years

Last updated June 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.